Avalyn Pharma Inc. (AVLN)
NASDAQ: AVLN · Real-Time Price · USD
29.76
-0.52 (-1.72%)
Nov 16, 2026, 4:00 PM EST - Market closed

Avalyn Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Selling, General & Admin
23.3414.689.96
Research & Development
94.4376.6145.76
Operating Expenses
117.7791.2955.72
Operating Income
-117.77-91.29-55.72
Interest & Investment Income
9.096.187.44
Other Non Operating Income (Expenses)
-0.06-0.09-0.02
EBT Excluding Unusual Items
-109.39-85.2-48.3
Gain (Loss) on Sale of Assets
---0.05
Legal Settlements
---1.4
Pretax Income
-109.39-85.2-49.74
Net Income
-109.39-85.2-49.74
Net Income to Common
-109.39-85.2-49.74
Net Income Growth
---
Shares Outstanding (Basic)
1910
Shares Outstanding (Diluted)
1910
Shares Change
-259.46%-
EPS (Basic)
-5.69-87.74-184.14
EPS (Diluted)
-5.69-87.74-184.14
EPS Growth
---

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Free Cash Flow
-107.35-81.83-48.46
Free Cash Flow Per Share
-5.58-84.27-179.40
EBITDA
-117.48-91.25-55.69
D&A For EBITDA
0.290.040.03
EBIT
-117.77-91.29-55.72
SEC Filings: 10-K · 10-Q